Literature DB >> 6219619

Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.

P K Yu, R S Edson, J A Washington, P E Hermans.   

Abstract

The bactericidal activity of moxalactam, alone and in combination with gentamicin, was studied with macrobroth two-dimensional checkerboard and killing curve techniques against gentamicin-resistant and -susceptible strains of Pseudomonas aeruginosa. Moxalactam was bactericidal at concentrations equal to or at least two to four times its inhibitory concentrations. Synergy at clinically applicable concentrations of moxalactam and gentamicin occurred with 6 of 14 gentamicin-resistant strains and 4 of 4 gentamicin-susceptible strains by the checkerboard technique and with 7 of 14 gentamicin-resistant strains by the killing curve technique. Synergy between moxalactam and gentamicin against gentamicin-resistant strains of P. aeruginosa is unpredictable and strain- and method-dependent.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6219619      PMCID: PMC184640          DOI: 10.1128/AAC.23.1.179

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin.

Authors:  G Archer; F R Fekety
Journal:  J Infect Dis       Date:  1977-09       Impact factor: 5.226

2.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

3.  Significance of antimicrobial synergism for the outcome of gram negative sepsis.

Authors:  J Klastersky; F Meunier-Carpentier; J M Prevost
Journal:  Am J Med Sci       Date:  1977 Mar-Apr       Impact factor: 2.378

4.  Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.

Authors:  R E Scott; H G Robson
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

5.  Pseudomonas bacteremia. Review of 108 cases.

Authors:  M R Flick; L E Cluff
Journal:  Am J Med       Date:  1976-04       Impact factor: 4.965

6.  In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli.

Authors:  D G Delgado; C J Brau; C G Cobbs; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

7.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

8.  Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

9.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

10.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

View more
  8 in total

Review 1.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

2.  Synergistic activity of aminoglycoside-beta-lactam combinations against Pseudomonas aeruginosa with an unusual aminoglycoside antibiogram.

Authors:  R B Clark; C B Pakiz; M K Hostetter
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

3.  In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.

Authors:  H Giamarellou; N P Zissis; G Tagari; J Bouzos
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

4.  In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.

Authors:  M A Buesing; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

5.  Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa.

Authors:  K Takahashi; H Kanno
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

6.  In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.

Authors:  C Watanakunakorn
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

7.  In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.

Authors:  P Angehrn
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

Review 8.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.